MiRNA therapeutics based on logic circuits of biological pathways
暂无分享,去创建一个
Antonino Fiannaca | Riccardo Rizzo | Alfonso Urso | Valeria Boscaino | Laura La Paglia | Massimo La Rosa | R. Rizzo | L. La Paglia | A. Fiannaca | A. Urso | Massimo La Rosa | Valeria Boscaino | Laura La Paglia
[1] A. Tolcher,et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Rossi,et al. The potential role of mTOR inhibitors in non-small cell lung cancer. , 2008, The oncologist.
[3] A. Datta,et al. From biological pathways to regulatory networks , 2010, 49th IEEE Conference on Decision and Control (CDC).
[4] P. Starostik,et al. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. , 2015, Archives of pathology & laboratory medicine.
[5] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[6] Gaetano Rocco,et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.
[7] C. Gridelli,et al. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] L. J. Veer,et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.
[9] Wei Zhong,et al. Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer , 2018, Thoracic cancer.
[10] Li Ding,et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.
[11] Hsien-Da Huang,et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions , 2017, Nucleic Acids Res..
[12] F. Slack,et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Francesca D. Ciccarelli,et al. NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings , 2015, Nucleic Acids Res..
[14] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[15] Antoni Ribas,et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.
[16] George A. Calin,et al. microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.
[17] R. Sahu,et al. MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention , 2018, The Journal of Pharmacology and Experimental Therapeutics.
[18] Dong Sun Kim,et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.
[19] Judy Lieberman,et al. Micromanaging hepatitis C virus. , 2013, The New England journal of medicine.
[20] K. Rauen,et al. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome , 2011, Clinical genetics.
[21] S. Khatri,et al. Application of Max-SAT-based ATPG to optimal cancer therapy design , 2012, BMC Genomics.
[22] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[23] Minoru Kanehisa,et al. KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..
[24] J. E. Kim,et al. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer , 2016, Biological reviews of the Cambridge Philosophical Society.
[25] Jacqueline L Olin,et al. Alectinib for advanced ALK-positive non-small-cell lung cancer. , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] Zhongming Zhao,et al. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes , 2015, Nucleic Acids Res..
[27] N. Socci,et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.
[28] C. Croce,et al. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. , 2009, Blood.
[29] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.
[30] Matthias Rothmund,et al. CDKN2A Germline Mutations in Familial Pancreatic Cancer , 2002, Annals of surgery.
[31] Chao Huang,et al. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. , 2018, Lung cancer.
[32] Seyed Javad Mowla,et al. Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. , 2016, The international journal of biochemistry & cell biology.
[33] Antonio Marchetti,et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features , 2006, International journal of cancer.
[34] S. Popat,et al. Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2018, The New England journal of medicine.
[35] Silvia Catuogno,et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] N. Rajewsky,et al. Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.
[37] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[38] Yang Zhao,et al. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials , 2018, Journal of Cancer.
[39] Ning Liu,et al. Regulation of let-7 and its target oncogenes (Review). , 2012, Oncology letters.
[40] Antonino Fiannaca,et al. miRTissue: a web application for the analysis of miRNA-target interactions in human tissues , 2018, BMC Bioinformatics.
[41] P. Khavari,et al. Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.
[42] Ji Luo,et al. Development of siRNA payloads to target KRAS-mutant cancer. , 2014, Cancer discovery.
[43] Stefano Volinia,et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. , 2009, International journal of oncology.
[44] Massimo Libra,et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). , 2009, International journal of oncology.
[45] A. Bosserhoff,et al. Role of miRNAs in the progression of malignant melanoma , 2009, British Journal of Cancer.
[46] Jun Li,et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways , 2016, Oncotarget.
[47] Alessandro Beghini,et al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. , 2010, Neoplasia.
[48] Roy Parker,et al. The Two Faces of miRNA , 2007, Science.
[49] Michael F. Olson,et al. RAS and RHO GTPases in G1-phase cell-cycle regulation , 2004, Nature Reviews Molecular Cell Biology.
[50] Carl Burch,et al. Logisim: a graphical system for logic circuit design and simulation , 2002, JERC.
[51] F. Slack,et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.
[52] Aniruddha Datta,et al. Hypoxia Stress Response Pathways: Modeling and Targeted Therapy , 2017, IEEE Journal of Biomedical and Health Informatics.
[53] Aniruddha Datta,et al. Systems biology Advance Access publication December 30, 2010 Cancer therapy design based on pathway logic , 2022 .
[54] Ghayda M. Mirzaa,et al. PIK3CA-Related Segmental Overgrowth , 2013 .
[55] Thomas D. Schmittgen,et al. microRNA Replacement Therapy for Cancer , 2011, Pharmaceutical Research.
[56] Aniruddha Datta,et al. Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer , 2017, BMC Bioinformatics.
[57] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[58] Edwin Cuppen,et al. A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability , 2012, PloS one.
[59] Phillip A Sharp,et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.
[60] Tae Min Kim,et al. An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer , 2016 .
[61] Aniruddha Datta,et al. A Model for Cancer Tissue Heterogeneity , 2014, IEEE Transactions on Biomedical Engineering.
[62] María Martín,et al. UniProt: A hub for protein information , 2015 .
[63] Ken R. Bracke,et al. miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD , 2020, Frontiers in Medicine.
[64] Mitsuo Sato,et al. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells , 2015, Cancer medicine.
[65] Aniruddha Datta,et al. Using the message passing algorithm on discrete data to detect faults in boolean regulatory networks , 2014, Algorithms for Molecular Biology.
[66] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[67] Y. Yatabe,et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.
[68] Manfred Kunz,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.
[69] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[70] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[71] The Uniprot Consortium,et al. UniProt: a hub for protein information , 2014, Nucleic Acids Res..
[72] T. Catela Ivković,et al. microRNAs as cancer therapeutics: A step closer to clinical application. , 2017, Cancer letters.
[73] Franck Morin,et al. Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study , 2018, European Respiratory Journal.
[74] Ping Yang,et al. miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican , 2017, Experimental and therapeutic medicine.
[75] F. Slack,et al. Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.
[76] J. Chorostowska-Wynimko,et al. miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives , 2017, Targeted Oncology.
[77] Edward B. Garon,et al. Targeting MEK for the treatment of non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[78] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[79] Matteo Bottai,et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma , 2018, PloS one.
[80] H. Groen,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[81] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[82] Dara L. Aisner,et al. Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung , 2018, Cold Spring Harbor molecular case studies.